**Stakeholders Group representativeness versus main thematic list of the SRIA**

The current configuration of the Stakeholders Group provides representation of key themes proposed in the SRIA such as IAVI (HIV), TB alliance (TB) and ARM Action Fund (AMR). Some stakeholders have a broader mandate, including access to medicines through Medicines for Africa or GLOPID-R, focusing on investments in research related to new r re-emerging infectious diseases. Other stakeholders have a cross-cutting Public Health mandate and include the European Center for Disease Control, PATH, Future for Africa, University of Amsterdam (Global Health) or the Rwanda Biomedical Centre (Annex I).

Gaps of representation have been identified in terms thematic expertise when compared with the SRIA, notably and not exclusively for Malaria, NTDs, climate crisis-related infectious diseases, lower-respiratory tract infections. In addition, a sub-representation of some sectors, such as local production, industry, regulating agencies, capacity building, networks representatives, policy-makers, health security stakeholders, vulnerable populations or CSOs from Europe and Africa are missing. The SRIA thematic mapping can be found in annex II.

Furthermore, the number of eligible and selected representatives is totaling 10, which limits the width of stakeholders providing inputs to the different strategic documents and discussions.

We thus suggest to launch a second call for Expression of Interest to increase the size and representativeness of the established Stakeholders Group. In addition, we may also reach out to stakeholder organisations to invite them to submit candidatures through this call for Expression of Interest, as per the list in annex III. In case the Governing Board wishes to update the list of proposed targeted stakeholders, many thanks for sharing any stakeholder name by 10 May 2023.

Should this not satisfy representation, we suggest to consider individual appointments as per the Governing Board recommendations.

**Annex I. Current composition of the Stakeholders Group (Post 1st call for Expression of Interest)**

**Annex II. EDCTP3 SRIA thematic mapping**

|  |  |  |  |
| --- | --- | --- | --- |
| **Diseases** | **Research / environment** | **Countermeasures** | **Collaboration** |
| **Main themes** |
| HIV | Clinical trials | Diagnostics | North-North; North-South; South-South collaboration |
| TB | Clinical research | Preventive tools | Networks of excellence |
| Malaria | Clinical evaluation | Vaccines | Regional networks |
| Neglected infectious diseases | Research capacity | Treatments |  |
| Diarrheal diseases | Capacity building | Regulatory capacity |  |
| Lower respiratory tract infections | Product-focused implementation studies | Innovation |  |
| (re)-emerging infectious diseases | Implementation research |  |  |
| Climate crisis-related infectious diseases | Epidemiological studies |  |  |
| Antimicrobial resistance | Institutional infrastructure development |  |  |
| Drug resistant infections | Epidemiologist training |  |  |
| NCDs | Ethics capacity |  |  |
| Poverty-related IDs |  |  |  |
| **Secondary themes** |
| Co-infections |  | Late stage products development |  |
| Co-morbidities |  | Product development partnership |  |
| Ebola |  | Novel drug treatment and formulations |  |
| Lassa fever |  |  |  |
| Yellow fever |  |  |  |
| Marburg |  |  |  |
| SARS-CoV-2 |  |  |  |
| **Overarching themes** |
| Evidence based decision making |
| Individual, social, economic burden |
| Health security |
| Environmental change |
| Climate crisis |
| Access to care |
| SDG3 |
| Vulnerable populations |

**Annex III: List of proposed targeted stakeholders**

|  |  |
| --- | --- |
|  | Stakeholders |
| 1 | WHO:TDRGAP-FAfroScience division HQOther divisions HQ to be considered per topic |
| 2 | Africa Academy of Science (AAS) |
| 3 | African Field Epidemiology Network (AFENET) |
| 4 | Africa Hub Business (AHB) |
| 5 | ADS Vaccine Advocacy Coalition (AVAC) |
| 6 | African Society for Laboratory Medicine (ASLM) |
| 7 | AUDA-NEPAD |
| 8 | Clinique Research |
| 9 | Ethixpert and COHRED |
| 10 | Global Forum for Bioethics in Research (GFBR) |
| 11 | Gulbenkian Foundation |
| 12 | Human Sciences Research Council South Africa |
| 13 | INDEPTH network |
| 14 | International Centre for Genomic Engineering and Biotechnology (ICGEB) |
| 15 | IQVIA |
| 16 | Pan-African Bioethics Initiative (PABIN) |
| 17 | Pharmalys |
| 18 | Treatment Action Group (TAG) |
| 19 | WHO – African Veccine Regulators Forum (AVAREF) |
| 20 | Selection of National Public Health Institutes (EU and Africa?) |
| 21 | DNDi |
| 22 | CEPI |
| 23 | Africa CDC |
| 24 | Medicine Patent Pool (MPP) |
| 25 | Save the Children |
| 26 | IANPHI (Itl Association of National Public Health Institutes) |
| 27 | climate and health alliance |
| 28 | CSO Representative drug access (Fifa Rahman) |
| 29 | NCD - [unitar](https://unitar.org/sustainable-development-goals/the-defeat-ncd-partnership) |
| 30 | Botnar Foundation |
| 31 | Pandemic Action network |
| 32 | International federation of Pharmaceutical Manufacturers (IFPMA) |
| 33 | Rockfeller Foundation |
| 34 | Global AMR R&D Hub |
| 35 | Pasteur Institutes network |
| 36 | African Union research/higher education |
| 37 | World Patient Alliance |
| 38 | International Society for Infectious Diseases (ISID) |
| 39 | European Public Health Association |
| 40 | Medecins Sans Frontieres |
| 41 | Medecins du Monde |
| 42 | DSW |
| 43 | Global Health Advocates |
| 44 | AVAREF |
| 45 | African Society for Laboratory Medicine (ASLM) |
| 46 | International Society of Pharmacovigilence (ISoP) |
| 47 | Medicines for Malaria Venture (MMV) |
| 48 | African Medicines Agency |
| 49 | European Medicines Agency |
| 50 | GAFFI (Global Action for Fungal Infections) |
| 51 | COVID19Clinical Research Coalition |
| 52 | FIND |
| 53 | Africa Health Diagnostics Platform |
| 54 | Aidsfond |
| 55 | European Health Forum Gastein (EHFG) |
| 56 | Agence Europeen pour le Developpement et la sante (AEDES) |
| 57 | One Campaign |
| 58 | AMREF Health Africa |
| 59 | European Public Health Alliance (EPHA) |
| 60 | Global Change Network |
| 61 | Instituto de Salud Global (ISGlobal) |
| 62 | Council on Health Research for Development (COHRED) |
| 63 | European Alliance for Responsible R&D and Affordable Medicines |
| 64 | UNFPA Supplies, UNICEF, IPPF |